Clinical Trial Update: Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating niraparib in combination with bevacizumab for ovarian cancer after complete cytoreduction; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Niraparib (Niraparib)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING